Physician

Benjamin John Miriovsky, M.D.

According to 2025 Medicare claims, Benjamin Miriovsky, M.D. (NPI: 1427234277) practices hematology/oncology in the Huntsville, AL market, with the plurality of this provider's patient population coming from Madison, AL. This provider's primary affiliated billing organization is ONCOLOGY SPECIALTIES, P.C. (NPI: 1669425716; TIN: 630897317) and primary practice location at 35801-3495.

Miriovsky's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 879 traditional Medicare patients, billed 181,611 HCPCS/CPT codes, and received $3,615,624 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,911 prescription claims across 261 beneficiaries totaling $3,886,495 in drug costs, led by Xtandi (Enzalutamide). 2023 DME data shows 54 claims. Open Payments data shows 62 records totaling $1,351. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $677,251 to $3,615,624. Similarly, Part D prescription costs have risen steadily, from $797,033 to $3,886,495. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $750 to $2,950.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,101	74,556	$677,251
2016	369	67,042	$1,022,164
2017	383	85,482	$1,626,930
2018	455	96,143	$1,921,776
2019	513	105,226	$2,298,429
2020	572	90,783	$2,056,550
2021	599	88,486	$1,372,194
2022	995	216,591	$3,430,787
2023	1,012	212,304	$3,449,094
2024	879	181,611	$3,615,624

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	1,037	3,515	$797,033
2016	652	2,072	$484,344
2017	195	1,132	$985,156
2018	223	1,353	$1,829,778
2019	258	1,243	$1,212,510
2020	256	1,170	$1,419,814
2021	269	1,167	$1,850,623
2022	316	1,748	$2,713,209
2023	262	1,783	$3,062,275
2024	261	1,911	$3,886,495

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	68	$56,103
2016	N/R	35	$18,440
2017	N/R	12	$8,383
2018	N/R	N/R	N/R
2019	N/R	33	$4,281
2020	N/R	N/R	N/R
2021	N/R	17	$1,189
2022	N/R	N/R	N/R
2023	N/R	54	$80,412
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	305	841	$90
82728	Ferritin (blood protein) level	297	547	$13
80053	Blood test, comprehensive group of blood chemicals	698	1,808	$10
36415	Insertion of needle into vein for collection of blood sample	680	1,733	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	703	1,862	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	39	1,170	$496,358
Ibrance	Palbociclib	28	784	$341,550
Erleada	Apalutamide	20	600	$291,810
Besremi	Ropeginterferon Alfa-2b-Njft	17	406	$242,821
Pomalyst	Pomalidomide	12	329	$237,131

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	62	$1,351	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Benjamin John Miriovsky, M.D.?

Tedicare shows public-source Medicare data for Benjamin John Miriovsky, M.D. (NPI 1427234277), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Benjamin John Miriovsky, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Benjamin John Miriovsky, M.D.?

Benjamin John Miriovsky, M.D. is linked to ONCOLOGY SPECIALTIES, P.C. (billing NPI 1669425716) in the available physician profile data.

Does Benjamin John Miriovsky, M.D. have Open Payments data?

Benjamin John Miriovsky, M.D. has 62 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.